Results 21 to 30 of about 354,411 (314)

Angiotensin-Converting Enzyme Inhibitor Does Not Suppress Renal Angiotensin II Levels in Angiotensin I–Infused Rats

Journal of Pharmacological Sciences, 2013
Angiotensin II (Ang II) infusion into rats elevates local angiotensin II levels through an AT1 receptor–dependent pathway in the kidney. We examined whether treatment with an angiotensin-converting enzyme (ACE) inhibitor, temocapril, or an AT1-receptor ...
Keisuke Ohnishi, Miki Murase, Daisuke Nakano, Nicolas Pelisch, Hirofumi Hitomi, Hiroyuki Kobori, Satoshi Morimoto, Hirohito Mori, Tsutomu Masaki, Koji Ohmori, Masakazu Kohno, Atsuhiro Ichihara, Akira Nishiyama   +12 more
doaj   +1 more source

Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function [PDF]

, 2014
<b>Objective:</b><p></p> Mitochondria-derived reactive oxygen species (ROS) play important roles in the development of cardiovascular disease highlighting the need for novel targeted therapies.
Adlam, Cai, Calhoun, Chacko, Chandran, DAgostino, Dai, Dai, Dikalova, Doughan, Evans, Flores-Munoz, Flores-Munoz, Gane, Graham, Graham, Gutierrez, Halliwell, Jalil, Jeffs, Landmesser, London, Lowes, Mercer, Messerli, Murphy, Murphy, Nakagami, Nakamura, Nozoe, Qin, Rajagopalan, Roman, Ross, Snow, Watkins, Winterbourn, Yang, Yasunari, Zhang, Zhang, Zorov   +41 more
core   +1 more source

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

Critical Care, 2020
Background In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to severe vasodilation, provide novel insights into its biology, and predict clinical ...
Rinaldo Bellomo, Richard G. Wunderink, Harold Szerlip, Shane W. English, Laurence W. Busse, Adam M. Deane, Ashish K. Khanna, Michael T. McCurdy, Marlies Ostermann, Paul J. Young, Damian R. Handisides, Lakhmir S. Chawla, George F. Tidmarsh, Timothy E. Albertson   +13 more
doaj   +1 more source

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model [PDF]

, 2016
Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals.
Akkerhuis, KM, Bertrand, ME, Boersma, E, Brugts, JJ, Danser, AHJ, De Maat, M, Ferrari, R, Fox, KM, Oemrawsingh, RM, PERGENE investigators, Redekop, WK, Remme, WJ, Rudez, G, Simoons, ML, Van Vark, LC   +14 more
core   +1 more source

In vivo antihypertensive mechanism of lactoferrin-derived peptides: Reversion of angiotensin I- and angiotensin II-induced hypertension in Wistar rats [PDF]

, 2015
Novel peptides with antihypertensive effects in SHR rats have previously been identified in lactoferrin (LF) hydrolysates. To investigate their in vivo antihypertensive mechanism, we have assessed the blood pressure lowering effects of two of these LF ...
Castelló-Ruiz, María, García Tejedor, Aurora, Gimeno Alcañiz, José Vicente, Manzanares, Paloma, Salom, Juan B.   +4 more
core   +1 more source

IRW (Isoleucine–Arginine–Tryptophan) Improves Glucose Tolerance in High Fat Diet Fed C57BL/6 Mice via Activation of Insulin Signaling and AMPK Pathways in Skeletal Muscle

Biomedicines, 2022
IRW (Isoleucine–Arginine–Tryptophan), has antihypertensive and anti-inflammatory properties in cells and animal models and prevents angiotensin-II- and tumor necrosis factor (TNF)-α-induced insulin resistance (IR) in vitro. We investigated the effects of
Stepheny C. de Campos Zani, Myoungjin Son, Khushwant S. Bhullar, Catherine B. Chan, Jianping Wu   +4 more
doaj   +1 more source

Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection.

PLoS ONE, 2021
BackgroundCoronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (AT1R-
Yonghou Jiang, Fergal Duffy, Jennifer Hadlock, Andrew Raappana, Sheila Styrchak, Ingrid Beck, Fred D Mast, Leslie R Miller, William Chour, John Houck, Blair Armistead, Venkata R Duvvuri, Winnie Yeung, Micaela Haglund, Jackson Wallner, Julie A Wallick, Samantha Hardy, Alyssa Oldroyd, Daisy Ko, Ana Gervassi, Kim M Murray, Henry Kaplan, John D Aitchison, James R Heath, D Noah Sather, Jason D Goldman, Lisa Frenkel, Whitney E Harrington   +27 more
doaj   +2 more sources

Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19

Journal of Ideas in Health, 2021
Currently, there is a persisting dispute regarding the renin-angiotensin-aldosterone-system (RAAS) inhibitors' safety of use in COVID-19 pandemics. On one side, RAAS inhibitors appear to determine an overexpression of ACE2, the receptor of SARS-CoV-2 ...
Angela Madalina Lazar
doaj   +1 more source

Annihilator Banach ∗-algebras and the Peter-Weyl theorem [PDF]

, 1976
The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on ...
Dennis Wildfogel, Barnes, Barnes, Barnes, Dixmier, Halmos, Hewitt, Kaplansky, Loomis, Naimark, Rickart, Wildfogel, Wildfogel, Yood, Yood, Yood   +15 more
core   +2 more sources

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy

Molecules, 2021
The octapeptide hormone angiotensin II is one of the most studied peptides with the aim of designing and synthesizing non-peptide mimetics for oral administration.
John Matsoukas, Vasso Apostolopoulos, Anthony Zulli, Graham Moore, Konstantinos Kelaidonis, Kalliopi Moschovou, Thomas Mavromoustakos   +6 more
doaj   +1 more source